Correvio Pharma Corp. Finite-Lived Intangible Asset, Expected Amortization, Year Four
Correvio Pharma Corp. had Finite-Lived Intangible Asset, Expected Amortization, Year Four of $3.65 million as of 2019-12-31, per its 20-F filed 2020-04-30.
Discontinued › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, after Accumulated Amortization, Estimated Amortization Expense, Fiscal Year Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour · last filed 2020-04-30
- 2019-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year Four $3.65M.
- 2018-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year Four $3.74M.
- 2017-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year Four $3.57M.
- 2016-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year Four $3.08M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Year Four |
|---|---|
| 2019-12-31 | $3.65M 20-F · filed 2020-04-30 |
| 2018-12-31 | $3.74M 40-F · filed 2019-03-13 |
| 2017-12-31 | $3.57M 20-F · filed 2018-04-30 |
| 2016-12-31 | $3.08M 40-F · filed 2017-03-29 |
| 2015-12-31 | $1.82M 40-F · filed 2016-03-29 |
| 2014-12-31 | $1.83M 40-F · filed 2015-03-27 |
| 2013-12-31 | $1.86M 40-F/A · filed 2014-04-30 |
| 2012-12-31 | $164.00K 20-F/A · filed 2013-04-18 |